Clinical and immunological parallels in patients with psoriasis during treatment with infliximab

Kurdina M.I.; Makarenko L.A.; Polianskaia A.A.

doi:https://doi.org/

Kurdina M.I.

Fakul'tet fundamental'noĭ meditsiny Moskovskogo gosudarstvennogo universiteta im. M.V. Lomonosova;
FGU TsKBp UD Prezidenta RF, Moskva

Makarenko L.A.

M.V. Lomonosov Moscow State University

Polianskaia A.A.

M.V. Lomonosov Moscow State University

Clinical and immunological parallels in patients with psoriasis during treatment with infliximab

Authors:

Kurdina M.I., Makarenko L.A., Polianskaia A.A.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2010;8(2): 77‑80

Read: 763 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kurdina MI, Makarenko LA, Polianskaia AA. Clinical and immunological parallels in patients with psoriasis during treatment with infliximab. Russian Journal of Clinical Dermatology and Venereology. 2010;8(2):77‑80. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Psoriasis: analysis of comorbid pathology. Russian Journal of Clinical Dermatology and Venereology. 2025;(1):16-21

Search of diagnostic and prognostic biomarkers of immunoinflammatory dermatoses by means of flow cytometry. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):170-177

Nucleotide sequence variants in IL4 and TNFA genes in patients with dermatoses and xerosis. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):178-184

Historical aspects and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):284-292

Key specific tools for assessment of life quality of patients with psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):319-325

Psychodermatological aspects of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):403-411

New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):453-460

Persistence of skin process remission in patients with moderate and severe psoriasis vulgaris in application of netakimab: a five-year observational study results. Russian Journal of Clinical Dermatology and Venereology. 2025;(4):462-468

Development of a predictive model for the identification of patients with high risk of psoriatic arthritis and assessment of the efficacy of early treatment with netakimab, IL-17A inhibitor. Russian Journal of Clinical Dermatology and Venereology. 2025;(5):625-634

Features of peripheral blood lymphocyte subpopulation profile in children with newly diagnosed untreated retinoblastoma. Russian Annals of Ophthalmology. 2025;(4):5-11

Abstract:

Keywords:

psoriasis

immune status

infliximab

Authors:

Kurdina M.I.

Fakul'tet fundamental'noĭ meditsiny Moskovskogo gosudarstvennogo universiteta im. M.V. Lomonosova;
FGU TsKBp UD Prezidenta RF, Moskva

Makarenko L.A.

M.V. Lomonosov Moscow State University

Polianskaia A.A.

M.V. Lomonosov Moscow State University

Close metadata

References:

Gisondi P., Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 8: 515-519.
Ortiz A., Yamauchi P.S. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. Skinmed 2006; 5: 285-288.
Kurdina M.I., Anofrieva N.V. Biologicheskie modifikatory immunnogo otveta pri psoriaze (sravnitel'nyi analiz effektivnosti i bezopasnosti). Ros zhurn kozh ven bol 2007; 5: 62-68.
Imametdinova G.R., Lukina G.V., Nasonov E.L. i dr. Opyt lecheniya revmatoidnogo artrita preparatom Remikeid (infliksimab). Rus med zhurn 2005; 24: 1590-1594.
Kurdina M.I. Antitsitokinovaya terapiya psoriaza – shag v budushchee. Farmateka 2004; 7: 59-65.
Antoni C.E., Kavanaugh A., Kirkham B. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 4: 1227-1236.
Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 8: 1150-1157.
Chaudhari U., Romano P., Mulcahy L. D. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 9271: 1842-1847.
Esters N., Vermeire S., Joossens S. et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 6: 1458-1462.
Glinski W., Stepien-Sopniewska B., Majewski S.et al. Alterations of T-cell: extracellular matrix proteins interactions in psoriasis. Immunol Lett 1993; 35: 2: 153 -157.
Gottlieb A. B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 4: 534-542.
Prens E., Debets R., Hegmans J. T lymphocytes in psoriasis. Clin Dermatol 1995; 13: 2: 115-129.
Scali J.J., Visentini S., Salomón J. et al. Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. Ann N Y Acad Sci 2007; 1110: 389-401.
Braun J., Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther 2003; 3: 1: 141-168.
Mayanskii D.N. Khronicheskoe vospalenie. M: Meditsina 1991; 271.
Langewouters A.M., van Erp P.E., de Jong E.M., van de Kerkhof P.C. Lymphocyte subsets in peripheral blood of patients with moderate-to-severe versus mild plaque psoriasis. Arch Dermatol Res 2008; 300: 3: 107-113.
Goan S.R., Volk H.D., Eichhorn I., Diezel W. Differences in interferon-gamma response of psoriatic lymphocytes to stimulation with various mitogens. Biomed Biochim Acta 1986; 45: 7: 903-906.
Ozturk G., Erbas D., Gelir E. et al. Natural killer cell activity, serum immunoglobulins, complement proteins, and zinc levels in patients with psoriasis vulgaris. Immunol Invest 2001; 30: 3: 181-190.
Milevskaya S.G., Potapova G.V. Kharakteristika immunnykh kompleksov u bol'nykh psoriazom. Vestn dermatol venerol 1998; 5: 35-37.
Laurent M.R., Panayi G.S., Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 1981; 40: 1: 66-69.
Toruniowa V. Humoral indices of the inflammatory process in psoriasis. Pol Tyg Lek 1992; 2: 44-45.
Kutukculer N., Yuksel S.E., Aksu G., Alper S. Autoantibodies other than antineutrophil cytoplasmic antibodies are not positive in patients with psoriasis. J Dermatol 2005; 32: 3: 179-185.